EPISODE · Nov 11, 2010 · 31 MIN
A Closer Look at Egrifta, a Newly Approved Treatment for HIV-Associated Belly Fat Gain (Lipohypertrophy)
from This Month in HIV
On Nov. 10, Egrifta (tesamorelin) became the first drug approved in the U.S. to treat unusual fat gain, or lipohypertrophy, in people with HIV. In our latest episode of This Month in HIV, we talk with noted HIV researcher Daniel Berger, M.D., about how Egrifta works, who should take it, and what else we know to date about the treatment of lipohypertrophy.
Embed this episode
NOW PLAYING
A Closer Look at Egrifta, a Newly Approved Treatment for HIV-Associated Belly Fat Gain (Lipohypertrophy)
0:00
31:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of This Month in HIV?
This episode is 31 minutes long.
When was this This Month in HIV episode published?
This episode was published on November 11, 2010.
Can I download this This Month in HIV episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!